{"id":"enalapril-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Cough"},{"rate":"5-10","effect":"Dizziness"},{"rate":"1-5","effect":"Hyperkalemia"},{"rate":"2-5","effect":"Hypokalemia"},{"rate":"5-10","effect":"Hypotension"},{"rate":"5-10","effect":"Headache"},{"rate":"3-8","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enalapril blocks ACE, preventing conversion of angiotensin I to angiotensin II, which reduces vasoconstriction and aldosterone secretion. Hydrochlorothiazide increases urinary sodium and water loss, reducing blood volume and peripheral vascular resistance. The combination provides synergistic antihypertensive effects through complementary mechanisms.","oneSentence":"Enalapril inhibits angiotensin-converting enzyme (ACE) to reduce angiotensin II production, while hydrochlorothiazide acts as a thiazide diuretic to promote sodium and water excretion, together lowering blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:32:37.654Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"}]},"trialDetails":[{"nctId":"NCT06710600","phase":"NA","title":"Phototoxicity of Frequently Prescribed Medicines","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2022-09-22","conditions":"Phototoxicity","enrollment":12},{"nctId":"NCT03179163","phase":"PHASE1, PHASE2","title":"Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans","status":"TERMINATED","sponsor":"Penn State University","startDate":"2016-07-20","conditions":"Hypertension,Essential","enrollment":10},{"nctId":"NCT04952051","phase":"PHASE3","title":"Enalapril Folic Acid Tablets Combined With CCB or Diuretic to Prevent Stroke in Patients With Type H Hypertension","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2014-07-01","conditions":"Hypertension","enrollment":1000},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT01271985","phase":"PHASE3","title":"Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2011-02","conditions":"Cardiovascular Diseases","enrollment":8410},{"nctId":"NCT02088450","phase":"PHASE2","title":"Systolic Hypertension in Europe Placebo-Controlled Trial","status":"TERMINATED","sponsor":"KU Leuven","startDate":"1990-02","conditions":"Isolated Systolic Hypertension","enrollment":4695},{"nctId":"NCT02817503","phase":"PHASE4","title":"Feasibility Study of the Intensive Systolic Blood Pressure Control","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2015-12","conditions":"Hypertension, Hyperhomocysteinemia","enrollment":100},{"nctId":"NCT02214498","phase":"PHASE4","title":"Treatment of HYpertension: Morning Versus Evening","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2015-05","conditions":"Essential Hypertension","enrollment":120},{"nctId":"NCT00603590","phase":"PHASE2","title":"Phase II Study of Heart Polypill Safety and Efficacy in Primary Prevention of Cardiovascular Disease","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2006-11","conditions":"Cardiovascular Disease, Hypertension, Hyperlipidemia","enrollment":475},{"nctId":"NCT00160160","phase":"NA","title":"Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2004-10","conditions":"Hypertension, Type 2 Diabetes","enrollment":440},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52},{"nctId":"NCT00394394","phase":"PHASE2","title":"Antihypertensive Effectiveness of the Associations of Hydrochlorothiazide and Amiloride and Hydrochlorothiazide and Enalapril","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2005-02","conditions":"Hypertension","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":76,"reaction":"DRUG INTERACTION"},{"count":47,"reaction":"ACUTE KIDNEY INJURY"},{"count":41,"reaction":"HEADACHE"},{"count":41,"reaction":"HYPONATRAEMIA"},{"count":40,"reaction":"DIZZINESS"},{"count":38,"reaction":"DRUG INEFFECTIVE"},{"count":36,"reaction":"INSOMNIA"},{"count":32,"reaction":"FATIGUE"},{"count":28,"reaction":"SOMNOLENCE"},{"count":27,"reaction":"MALAISE"}],"_approvalHistory":[],"publicationCount":49,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["To be determined"],"phase":"marketed","status":"active","brandName":"Enalapril/hydrochlorothiazide","genericName":"Enalapril/hydrochlorothiazide","companyName":"Erasmus Medical Center","companyId":"erasmus-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enalapril inhibits angiotensin-converting enzyme (ACE) to reduce angiotensin II production, while hydrochlorothiazide acts as a thiazide diuretic to promote sodium and water excretion, together lowering blood pressure. Used for Hypertension, Heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}